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Background
In search of antiretrovirals with microbicide potential,
we have synthesized a library of non-nucleoside reverse
transcriptase inhibitors (NNRTIs), encompassing 71 tria-
zine analogues. We present data on the anti-HIV activity
and toxicity using a broad armamentarium of in vitro
assays and models.
Materials and methods
In a primary screen, the anti-HIV activity against the
laboratory strain Ba-L and against a primary subtype C
isolate was determined in the TZM-bl cell line. Cellular
toxicity on TZM-bl cells was evaluated using WST-1.
Subsequently, a selection of1 7c o m p o u n d sw a sf u r t h e r
evaluated for anti-HIV activity in different primary cells,
including peripheral blood mononuclear cells, dendritic
cells and CD4+ T lymphocytes. In addition, the activity
against NNRTI-resistantviruses (V106A, Y181C, L100I/
K103N) was tested. The toxicity profile was further
investigated using blood cells and epithelial cells origi-
nating from the female genital tract (FGT) and in a dual
chamber assay modeling the FGT and underlying muco-
sae. Finally, toxicity towards vaginal flora (reference
strains of L.vaginalis, L. iners, L. jensenii, L. gasseri, L.
crispatus,Avaginae, G. vaginalis) was measured for the
lead molecules UAMC00838 and UAMC01009. Dapivir-
ine (TMC120) was used as a bench mark throughout
the study.
Results
In TZM-bl cells, most of the compounds were highly
active against Ba-L and subtype C, with low nanomolar
EC50 values slightly above or below the EC50 of dapi-
virine (2.0 nM). Similar nM activities were found in pri-
mary cells for a selection of 17 compounds.
Interestingly, these compounds retained fairly good
potency (EC50 values = 1-300 nm) against a resistant
strain carrying the NNRTI-resistance mutations V106A
or Y181C. However, potency was diminished (submicro-
molar and micromolar EC50 values) when tested against
a mutant virus carrying L100I/K103N. Compounds
UAMC00838 and UAMC01009 were identified as lead
molecules based on their activity/toxicity profile and
chemical structure.
These novel compounds showed similar or better toxi-
city profiles as the bench mark molecule dapivirine, in
TZM-bl cells as well as in FGT epithelial cells and in a
dual chamber system modeling the FGT. Finally, while
no toxicity against vaginal lactobacilli was observed up
to concentrations approx. 80,000 times above the EC50
of compound UAMC00838, the growth of G. vaginalis
and A vaginae was inhibited at the highest compound
concentration. Compound UAMC01009 showed addi-
tional low level toxicity against L. iners and high level
toxicity against L. crispatus.
Conclusions
We present data of highly active NNRTIs with a favor-
able toxicity profiles compared to the bench mark
NNRTI dapivirine. Compound UAMC00838 does not
affect the normal vaginal flora, but could inhibit G. vagi-
nalis and A vaginae, which are associated with bacterial
vaginosis, a risk factor for HIV acquisition. Ongoing
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potential as intravaginal/-rectal microbicides.
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